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Although preventable, Cervical Cancer (CC) is the leading cause of cancer
deaths among women in Sub-Saharan Africa with the highest incidence in
East Africa. Kenyan guidelines recommend an immediate screen and treat
approach using either Pap smear or visual screening methods. However,
system (e.g., inadequate infrastructure, weak treatment, referral and tracking
systems) and patient (e.g., stigma, limited accessibility, finance) barriers to
comprehensive country wide screening continue to exist creating gaps in
the pathways of care. These gaps result in low rates of eligible women being
screened for CC and a high loss to follow up rate for treatment. The long-term
goal of 70% CC screening and treatment coverage can partly be achieved by
leveraging electronic health (eHealth, defined here as systems using Internet,
computer, or mobile applications to support the provision of health services)
to support service efficiency and client retention. To help address system
level barriers to CC screening treatment and follow up, our team developed
an eHealth tool—the Cancer Tracking System (CATSystem), to support CC
screening, treatment, and on-site and external referrals for reproductive age
women in Kenya. Preliminary data showed a higher proportion of women
enrolled in the CATSystem receiving clinically adequate (patients tested
positive were treated or rescreened to confirm negative within 3 months)
follow up after a positive/suspicious screening, compared to women in the
retrospective arm.
KEYWORDS

eHealth (mobile Health), system—level, cervical cancer screening, cervical cancer
treatment, Kenya, cervical cancer tracking
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Introduction

and long distances to travel for available services also pose
substantial challenges to treatment access (20).
eHealth and eHealth interventions have been widely
implemented in the past decade to support a range of healthrelated outcomes and have the potential to improve CC
screening and follow up care. In Kenya, eHealth interventions
have increased maternal retention in guideline-adherent
PMTCT services and on-time testing of infants exposed to
HIV (21, 22), and have improved postoperative circumcision
follow up (23). In Kenya, patients who received CC rescreening
reminders via SMS were eight times more likely to adhere
to scheduled rescreening than those who did not (24). In a
study evaluating the impact of sending CC screening results via
SMS or phone call, women found both options acceptable and
effective and resulted in higher treatment follow up than relying
on patient clinic visits to relay results (25). Adapting proven
eHealth strategies offers countries low cost strategies to address
persistent gaps in the continuum of CC care.

Cervical Cancer (CC) is preventable through HPV
vaccination and screening to detect precancerous lesions; yet in
2018, an estimated 570,000 cases were diagnosed and 311,000
deaths occurred globally (1). In Kenya, CC is the second leading
cancer in women, and the leading cancer-related death in
women. Around 5,250 new cases of CC are diagnosed annually,
and 3,200 women die of CC every year in Kenya (2).
Early detection and treatment of abnormalities and
precancers that are likely to progress to invasive carcinoma (3)
not only improves overall patient outcomes (5 year survival is
95.7 vs. 9.9% for CC diagnosed at stage 1a1 vs. stage IVb (4,
5) but also reduces the cost of treatment to the patient and
health system (USD $85 for stage 0 vs. $1575 for stage III
curative) (6). In most cases, CC is due to human papillomavirus
infection (7). When HPV infection persists, the time from initial
infection to development of high-grade cervical intraepithelial
neoplasia and, finally, invasive cancer takes an average of
15 years. This combined with the system and patient screening
barriers experienced in resource limited settings highlights
the importance of frequent screening to detect intraepithelial
disease, for prompt management. To achieve population level
health gains, the WHO recommends countries reach 70%
coverage with screening and 90% of those needing it receiving
treatment (8).
Although awareness of the importance of CC screening is
increasing (9), only 16–19% of eligible Kenyan women 18–
69 years old are screened for CC (10). These low rates of
screening contribute to 50–80% of cases identified in advanced
stages of CC (11–13). Due to low cost, Visual inspection with
acetic acid (VIA) and Visual inspection with Lugol’s iodine
(VILI) techniques are the most used screening methods in a
low resource settings like Kenya. Kenyan guidelines call for
a “screen and treat” protocol for women with pre-cancerous
lesions identified by VIA/VILI (when PAP or HPV testing is
unavailable), in which treatment is administered on the same
clinic visit as diagnosis to minimize patient burden, treatment
delay, and loss to follow-up (LTFU) (14). However, in a survey
of 12 hospitals across 7 counties, only 25% of facilities had
a functional cryotherapy machine (9), allowing them to offer
services compliant with these guidelines. Even amongst those
who offer same day services, supply stock outs, C02 shortages
for the cryotherapy machine, and lack of trained providers
available to perform the procedure can delay treatment and
cause increased burden on patients (15, 16). Of those who do
not receive same day services, only 20–53% of those diagnosed
returned for cryotherapy (15, 16). Indeed, in a multinational
study in sub-Saharan African capitals, only 15.8% of CC patients
received care with curative potential (17). Individual and
social barriers to treatment include concerns about side effects,
treatment−related fear and stigma, fear of marital discord,
religious and cultural beliefs, geographical location (rural vs.
urban), and limited knowledge (18, 19). Financial constraints
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Materials and methods
This study presents the findings from a pilot study utilizing
an eHealth tool—the Cancer Tracking System (CATSystem),
an adaptation of a web-based eHealth intervention called the
HIV Infant Tracking System (HITSystem) (21). Designed for
use in low to middle income settings, the primary goals of
the CATSystem are to (a) increase rates of CC screening, (b)
improve the treatment, referral (internal and external), and
follow up rates of women screened positive with precancerous
and cancerous lesions and c) identify missed re-screening
and treatment opportunities. Using algorithm driven alerts for
providers and SMS to patients, the CATSystem is designed to
support CC screening, treatment, and referrals for reproductive
age women (HIV + and HIV–) in Kenya. The system accesses
satellite broadband via modems, generates a provider dashboard
linking to patients who are overdue for a service or in need
of patient outreach, and sends automated customized text
messages to women to support screening and treatment followup per national Kenyan Ministry of Health guidelines (14).
Decentralized for data entry, authorized providers (mentor
mothers, data clerks, or clinicians) enter data in real-time at
implementing hospitals, allowing the generation of timely alerts
and provider follow up (patient tracing, phone calls, or SMS);
however, as a web-based intervention, centralized updates to
the programming of the system are automatically applied across
sites as they become available.

Study overview
This study was an observational study with historical
controls to evaluate an 11-month pilot of the CATSystem at one
provincial level hospital in Rift Valley, Kenya. The standard of
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invasive CC (chemotherapy, radiation, radical hysterectomy)
were referred to the highest tier referral hospitals. During this
time, hospital operations across the country were limited or
shut down due to multiple healthcare worker strikes (2019, Dec
2020–Feb 2021) and COVID-19 mitigation strategies (May–
June 2020) affecting daily hospital operations and pilot study
data collection. Data from enrolled participants were compared
to data from historical controls who were screened for CC
in the 6 months prior to CATSystem implementation April
2019–October 2019.

care at the facility includes paper-based record keeping for CC
screening (VILLI/VIA, pap smear and colposcopy) and on-site
treatment with cryotherapy and loop electrosurgical excision
procedure (LEEP). Patients needing chemotherapy or radiation
treatment are referred to Kenyatta National Hospital, in Nairobi,
which is approximately 160 km (3–4 h drive one-way) from
the study hospital.

Cancer tracking system intervention

Study participants

Adapted from the HITSystem, which is an eHealth
intervention that has proven effective in improving maternal
and infant HIV care in Kenya (21, 22), the CATSystem is
an eHealth intervention that aims to improve follow up after
an abnormal CC screen and increase rescreening rates per
Kenya Ministry of health Guidelines (see Figure 1). Women
are enrolled in the CATSystem through the comprehensive
HIV care centers (CCC) and maternal and child health/Family
Planning (MCH/FP) department. Demographic and contact
information are captured at the time of enrollment. The patient
is assessed for risk factors of CC including HIV status, age
of onset of sexual activity, number of sexual partners, history
of sexually transmitted infections, prior positive screenings, or
history of in situ carcinoma of the vulvar or vaginal epithelium.
Women are screened and those who have an abnormal CC
screen are ideally treated on the same day. If the patient is
unable to undergo same day treatment after a positive screen,
the system sends an automated SMS alerts prior to the scheduled
appointment and alerts in case of a missed appointment. They
are tracked until they complete clinically indicated care based on
their unique clinical presentation. After completing appropriate
management for suspicious malignancy/in situ carcinoma or
invasive malignancy, the patient continues to get automated
alerts for follow up care based on national guidelines. Women
who have a normal screen are prompted for rescreening at
the indicated interval. Algorithm-driven electronic alerts notify
clinical providers when patients are overdue or missing key
services (treatment, labs, follow up care, missed appointments).
The system also keeps a record of clinical findings, visual images
of the cervix and lab results from each encounter.
The CATSystem was piloted in the Comprehensive Care
Center (CCC, where HIV services are provided) and Maternal
and Child Health Departments (MCH) from October 22nd,
2019, to January 26th, 2021. These departments are the two
main points where CC screening occurs. The inclusion of the
CCC also allowed us recruit women living with HIV who are
vulnerable to CC due to the associated risk between HIV and
contracting the Human Papilloma Virus (HPV) (26, 27). Each
department had one or two nurses or clinical officers to conduct
screenings and cryotherapy treatments. The facility had two
gyno-oncologists to perform complicated procedures [biopsies,
loop electrosurgical excision procedure (LEEP)]. Treatments for
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All women ages 18–50 years who received CC screening in
CCC or MCH during the study period were eligible. Due to
the CATSystem’s use of SMS text messages, women also needed
cell phone access to participate in the study. All participants
provided written informed consent prior to study participation.
During the historical control period, paper CC screening
registries from CCC and MCH were reviewed. Data were
entered in an Excel spreadsheet by study staff. Although the
registries followed the required ministry of health format,
the data quality was highly variable regarding consistency,
completeness, and evidence of follow up. Where paper records
were incomplete, study staff followed up with providers to fill
in gaps as much as was possible and ensured that duplicate
records were reconciled; however, in many cases retrospective
data remained incomplete.

Study procedures
Clinic providers or study staff informed women presenting
for CC screening about the purpose of the CATSystem and asked
eligible women if they would like to participate in the study or
would prefer to receive standard of care (paper-based record
keeping without action alerts or communication). Participants’
demographic and place/s of residence information were
entered into the CATSystem upon enrollment. All subsequent
counseling and clinical care data (including appointments,
laboratory tests and results, treatment, rescreening) were
entered into the CATSystem by a study research assistant. The
CATSystem then used dates of services and other clinical criteria
(i.e., screening results, appointment dates) to trigger electronic
alerts to prompt providers when time-sensitive actions along
the CC cascade of care were needed (see Figure 2 for an
image of the dashboard). Clicking on each alert name would
bring up a list of patients requiring that service, allowing
providers to easily identify and initiate follow up among patients
with incomplete services. Alerts were only resolved once the
indicated action had taken place and had been recorded in the
CATSystem. Finally, an informal “lunch and learn” style group
discussion was held with providers (CCC Nurse, MCH Nurse,
MCH Clinical Officer, two Gyno-oncologists and Laboratory
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FIGURE 1

Kenya ministry of health national cervical cancer screening guidelines.

technician) where facilitators and challenges to utilization and
identified modifications to the CATSystem that could improve
its utility and implementation.

patients seen in settings where CC screening should have been
conducted prior to CATSystem implementation.

Analyses
Outcomes

Descriptive statistics were calculated for demographic
variables and risk factors for CC. Continuous variables
were expressed as mean ± SD where applicable. Due to
limitation in availability of historical control data, output
is only available for intervention arm demographic and
risk factor variables. The primary outcome was proportion
of patients with a positive screening obtaining clinically
appropriate care. A chi-square analysis was done on the
categorical outcome to determine significance. Data was
analyzed using SPSS v27.

The primary outcome of our study was “clinically
appropriate care” after an abnormal CC screen defined as
completion of any of the following actions: (1) Onsite treatment
for precancerous lesions, (2) onsite or referred LEEP treatment
for more severe precancerous lesions, (3) referral to a treatment
center if suspected of invasive cancer, or (4) treatment of
coinfections (e.g., cervicitis or STI), followed by a re-screen
with appropriate follow-up within 3 months. We compared the
pilot data to a 6-month retrospective record review of all female
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FIGURE 2

Cancer tracking system (CATSystem) dashboard.

FIGURE 3

Flow of cancer tracking system (CATSystem) participants through cervical cancer care. Blue boxes indicate completion of care. Yellow boxes
indicate loss to follow up prior to completion of care.

Results

50 patients, 4 (8%) received further care in the form of
clinically appropriate care that is, same day treatment by
cryotherapy, or referral to a higher center for gynecology
or oncology referral. Completion of referral treatment (i.e.,
surgery, radiation therapy, chemotherapy or other diagnostic
or therapeutic interventions) could not be obtained, hence
a documented referral for appropriate care was considered
clinically appropriate follow up.
In the CATSystem arm, 119 patients had an initial abnormal
screening result; of whom, 28 had a positive screen, of these, 10
received clinically appropriate care and 18 were lost to followup. Ninety-one patients had inconclusive results due to cervicitis
and required rescreening. Of these 91, 10 were positive upon

A total of 491 patients were enrolled during the intervention
period, and a total of 1,702 patient records were reviewed
during the control period. Patient demographics are shown in
Table 1. Due to lack of documentation in the CC registries,
most demographic variables for control site participants
were unavailable. The demographics collected through the
CATSystem, however, indicate that the right target population
were accessed during the pilot.
Among the 1,702 records screened in the control arm,
50 encounters had a documented positive screening test for
CC, either VIA/VILI or PAP Smear or both. Among these
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TABLE 1 Cancer tracking system (CATSystem) patient demographics.

Demographic

Intervention
N = 491

Control
N = 1,702

38.6 ± 10.7 years

39.5 ± 11.3 years

Primary education

180 (40.9%)

–

Secondary education

150 (34.1%)

–

University/college

110 (25.0%)

–

Less than 500 KES

196 (47.0%)

–

500–750 KES

64 (15.3%)

–

750–1,000 KES

36 (8.6%)

–

121 (29.0%)

–

9 (1.8%)

–

196 (46.8%)

–

28 (5.7%)

–

128 (26.1%)

–

Age

within the hospital, and (3) patient travel and treatment costs
delaying their return for treatment. Informal conversations
with providers confirmed the improvement in clinical care and
reinforced many of the facilitators and challenges to utilization
in the Kenyan context noted in the literature. Providers felt that
the CATSystem features (dashboard alerts of missed screening
and treatment appointments, pathology/lab results) gave them a
more comprehensive picture of where their patients were in the
cascade of care compared to the standard registers and allowed
them to follow up with patients more easily.
Many of the system and patient-level challenges were
outside the scope of the CATSystem and would need to be
addressed at the system level through training and/or policy
change. These challenges contributed to 61% of women not
receiving clinically appropriate care, even with enhanced follow
up through the CATSystem. While this is a drastic improvement
from the 96% loss to follow up observed in the retrospective
data, it highlights the urgent need for system and policy level
changes to address remaining gaps. Such actions to improve
could include: enhanced coverage for CC care through the
National Hospital Insurance Fund (NHIF); training dedicated
clinicians for CC screening and treatment services; prioritizing
data and data systems, ensuring the availability of resources
for CC screening and cryotherapy at all sub-county and higher
hospitals; funding of more CC treatment centers; increased
coordination between government, research, academic, and
NGO stakeholders (28, 29).
Unlike in HIV, funding for CC prevention activities is
not contingent on regular reporting, reducing the level of
accountability. As such current data reporting levels are
disjointed and incomplete contributing to the overall lack of
monitoring data in Kenya. In pre-intervention data review
of this study, the data quality was highly variable regarding
consistency, completeness and follow up. Both CCC and MCH
generally have one staff member tasked with carrying out the
screening and record keeping, which on busy days affected data
entry. Furthermore, for facility and county reporting purposes
just noting the number of negative and positive screens is often
adequate when reporting to county Ministries of Health. Once
patients are referred, informal conversations with providers
revealed that they are often too busy to follow up on the patient
with other departments or the patient themselves resulting in
a significant number of gaps in the paper registry. In addition,
record overlaps were possible between registries as patients
could be seen in both CCC and MCH departments. A way to
fill in the gaps would have been to follow up with the patients,
but due to limited staff and budget this was not possible. The
need for improved data and data systems has been well noted
(29, 30) and this is an area the National CC registry/board
want to improve (28). In our study, the CATSystem significantly
improved data quality and completeness and, indeed, was
designed to help address this gap. Furthermore, the CATSystem

Education

Weekly income

1,000–2,500 KES
History of vulvar or cervical
intraepithelial neoplasm
First sexual encounter 18 years of
age or earlier
History of sexually transmitted
infection
HIV positive at baseline

rescreening, 71 were negative, and 10 were lost to follow up.
Thus, a total of 38 patients had a documented positive screening
test. Of these 38, 15 (39.5%) received appropriate treatment
that is same day treatment by cryotherapy, thermocoagulation
or referral to higher center for further management (see
Figure 3). In the CATSystem arm, patients continued to
receive SMS reminders for re-visit for treatment or visit to a
tertiary care facility for continuation of care. Ultimately, the
CATSystem intervention led to a fivefold increase in the number
of patients receiving clinically appropriate care (p < 0.01),
after a positive screening result. That is, 15/38 (39.5%)
compared to 4/50 (8%) among standard of care participants
enrolled prior to CATSystem implementation received clinically
appropriate care.

Discussion
Preliminary evidence from this pilot study indicates that the
CATSystem is a promising tool that can help clinicians improve
rates of clinically appropriate treatment and follow up for
suspected and invasive CC. The primary outcome of the study
was the proportion of women with a positive screen result who
received clinically appropriate care for precancerous lesions.
With the CATSystem, we observed a fivefold improvement in
receipt of clinically appropriate care after a positive screen:
15/38 (39.5%) among CATSystem participants compared to
4/50 (8%) among standard of care participants enrolled prior
to CATSystem implementation. Despite these improvements,
significant challenges in the provision of CC screening and
care persisted at the system and patient level including: (1)
Limited capacity of CC screening providers which meant missed
screening, treatment and follow up opportunities, (2) a lack of
clear linkage channels between screening and treatment points
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include a cost analysis to assess the cost effectiveness of
the CATSystem providing an argument for scaling up to
other facilities.

was programmed with the potential to interact with the National
Center Registry, an ability that to our knowledge no other CC
eHealth technology in Kenya is currently able to do. Linking
these systems could contribute to a comprehensive database of
CC care and outcomes, nationally. Systems such as CATSystem
can be integral to addressing the noted gaps and improving the
CC cascade of care.
Early investments in screening can not only improve
outcomes for women, but also reduce costs associated with
later care and save lives. Public sectors costs for CC diagnostic
and treatment procedures are estimated at $180.00 and $85.00–
$1,500 (depending on stage), respectively (6). Studies report
that only about 9–20% of CC patients have NHIF (National
Health Insurance Fund) coverage, and this coverage is limited
in what it provides, leaving patients to foot a substantial
financial cost for treatment. At the main referral hospital
KNH, patients can pay as much as $100–$300 for MRI’S and
CT scans, and $300 per chemotherapy course, costs that are
prohibitive given the national income average of $641 per
month (31). Ultimately a multifaceted approach that includes
the scale up of both screening and treatment, investment in
data systems, and training is needed to address the burden of
CC in Kenya (31). However, ensuring timely screening and
rescreening through the less expensive VIA//VILI approach
can ultimately lead to early diagnosis and treatment leading
to reduced morbidity/mortality and preclude the need for
more expensive procedures. The CATSystem can help systemize
documentation and strengthen referral pathways; maximize the
existing investments in CC care.

Limitations
The COVID-19 pandemic and the fall out within the
health system including health worker strikes and limited
access affected implementation of the study, this could in
part account for the discrepancies we saw in numbers pre
and post the intervention (32). However, we contend that the
improvements are still noteworthy, especially given increased
challenges with accessing healthcare during the intervention
period due to COVID-19 restrictions. The incomplete CC
paper registries due to limited staffing and busy providers
as well as documentation errors made it difficult to collect
full patient CC screening records for comparison with the
system and we have no additional information on control
participants outside of what has been reported. With more
funding the work of following up with patients and other sources
can be feasible. However, these limitations in data represent
the standard of care in Kenyan facilities and emphasize the
need for improved system of data management. Furthermore,
the CATSystem is a passive system and can only reach the
population presenting for care at study hospitals and this
study only enrolled women presenting in MCH and CCC care.
We acknowledge this as a limitation in that women who do
not access care in these settings are represented in our study
and our data do not allow us to estimate the proportion of
women who may have been missed. We also do not have
any additional information on the number of characteristics of
women who were eligible for participation but chose not to
participate. While the women missed by our study may have
greater challenges accessing care and may bias our results, we
have no information on their characteristics to expand upon
this hypothesis. Rates of refusal will be more comprehensively
documented in the proposed R01 and a plan to conduct
community outreach to expand the reach of CATSystem
has been drafted.

Next steps
System-level and Intervention specific challenges,
barriers/opportunities were identified in the pilot study
that will be incorporated as we seek funding to conduct a
rigorous evaluation (randomized control trial) of the system
which will allow for longer follow up with more sites thus
increasing the generalizability of findings. System level changes
would include (1) working with facility, and local and national
ministry of health to provide continuing education around
CC screening, and (2) working with facility providers and
administrators to develop clear in hospital linkage channels
between screening and treatment points. Intervention-specific
changes would include identifying specific personnel to enter
data and based on informal conversations with providers the
following additions to the system: (1) Sending SMS reminders
not only to patients but to providers to remind when dashboard
alerts come into the system, (2) sending post- operative SMS
instructions after procedures such as colposcopy, LEEP and
cryotherapy, (3) providing frequent supervision support and
follow up training, and (4) setting up a data coordination
system between involved departments. Finally, we will also

Frontiers in Medicine

Conclusion
There was a fivefold increase in the rate of clinically
appropriate care after a positive screen among patients
enrolled in the CATSystem, compared to pre-intervention
data. Furthermore, it significantly improved data quality and
completeness, which represents a priority among national
stakeholders. Investing in systems to increase the rates of early
detection and treatment of precancerious lesions can improve
patients outcomes and ultimately reduce the costs associated
with significantly more costly treatment of later-stage detection.
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